Given our findings that VED-LYTACs effectively reduce VEGF levels, thereby mitigating VEGF-driven pathological angiogenesis and vascular permeability, we hypothesize that this aptamer-chimera construct could benefit wet AMD. This evidence concerns the gene VEGFA and wet macular degeneration.